NASDAQ · IMMX
Immix Biopharma, Inc.
$7.98-$0.15 (-1.78%)
Immix Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.15% below the high.
Loading market information…
NASDAQ · ATOS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Atossa Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.98% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Atossa Therapeutics, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.86. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Atossa Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 25, 2025 |
| -$0.75+16.67% vs estimate |
| $0.00 |
| Q3 2024 | Nov 12, 2024 | -$0.75-1,150.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.98-$0.15 (-1.78%)
Immix Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.15% below the high.
$19.00+$0.69 (+3.77%)
Greenwich LifeSciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.28% below the high.
$29.46-$0.89 (-2.93%)
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.13% below the high.
$3.30-$0.16 (-4.62%)
Whitehawk Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
$3.98-$0.08 (-1.97%)
Coya Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.88% below the high.
$0.74-$0.01 (-1.28%)
Cognition Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
$3.90-$0.13 (-3.23%)
Clene Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.11% below the high.
$6.83+$0.04 (+0.52%)
Instil Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.5% below the high.
